• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

靶向磷酸化 tau 蛋白 C 端丝氨酸区域的单克隆抗体的结构特征。

Structural characterization of monoclonal antibodies targeting C-terminal Ser region of phosphorylated tau protein.

机构信息

a Department of Biochemistry & Molecular Pharmacology , New York University School of Medicine , New York , NY , USA.

b Departments of Neuroscience & Physiology, & Psychiatry , New York University School of Medicine , New York , NY , USA.

出版信息

MAbs. 2019 Apr;11(3):477-488. doi: 10.1080/19420862.2019.1574530. Epub 2019 Feb 26.

DOI:10.1080/19420862.2019.1574530
PMID:30794086
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6512906/
Abstract

Targeting tau with immunotherapies is currently the most common approach taken in clinical trials of patients with Alzheimer's disease. The most prominent pathological feature of tau is its hyperphosphorylation, which may cause the protein to aggregate into toxic assemblies that collectively lead to neurodegeneration. Of the phospho-epitopes, the region around Ser/Ser has received particular attention for therapeutic targeting because of its prominence and stability in diseased tissue. Herein, we present the antigen-binding fragment (Fab)/epitope complex structures of three different monoclonal antibodies (mAbs) that target the pSer tau epitope region. Most notably, these structures reveal an antigen conformation similar to a previously described pathogenic tau epitope, pSer, which was shown to have a β-strand structure that may be linked to the seeding core in tau oligomers. In addition, we have previously reported on the similarly ordered conformation observed in a pSer epitope, which is in tandem with pSer. Our data are the first Fab structures of mAbs bound to this epitope region of the tau protein and support the existence of proteopathic tau conformations stabilized by specific phosphorylation events that are viable targets for immune modulation.

摘要

针对 tau 的免疫疗法是目前阿尔茨海默病患者临床试验中最常用的方法。tau 的最突出的病理特征是过度磷酸化,这可能导致蛋白质聚集成有毒的聚集物,从而导致神经退行性变。在磷酸化表位中,Ser/Ser 周围的区域因其在病变组织中的突出性和稳定性而受到特别关注,作为治疗靶点。在此,我们展示了针对 pSer tau 表位区域的三种不同单克隆抗体 (mAb) 的抗原结合片段 (Fab)/表位复合物结构。最值得注意的是,这些结构揭示了一种类似于先前描述的致病性 tau 表位 pSer 的抗原构象,该表位具有 β-折叠结构,可能与 tau 寡聚体中的种子核心有关。此外,我们之前还报道了在与 pSer 串联的 pSer 表位中观察到的类似有序构象。我们的数据是首次报道与 tau 蛋白该表位区域结合的 mAb 的 Fab 结构,并支持存在由特定磷酸化事件稳定的蛋白病变 tau 构象,这些构象是免疫调节的可行靶点。

相似文献

1
Structural characterization of monoclonal antibodies targeting C-terminal Ser region of phosphorylated tau protein.靶向磷酸化 tau 蛋白 C 端丝氨酸区域的单克隆抗体的结构特征。
MAbs. 2019 Apr;11(3):477-488. doi: 10.1080/19420862.2019.1574530. Epub 2019 Feb 26.
2
Tau Antibody Structure Reveals a Molecular Switch Defining a Pathological Conformation of the Tau Protein.tau 抗体结构揭示了一种分子开关,定义了 tau 蛋白的病理构象。
Sci Rep. 2018 Apr 18;8(1):6209. doi: 10.1038/s41598-018-24276-4.
3
Epitope mapping and structural basis for the recognition of phosphorylated tau by the anti-tau antibody AT8.抗tau蛋白抗体AT8识别磷酸化tau蛋白的表位图谱及结构基础
Proteins. 2016 Apr;84(4):427-34. doi: 10.1002/prot.24988. Epub 2016 Feb 5.
4
Monoclonal antibody PHF-9 recognizes phosphorylated serine 404 of tau protein and labels paired helical filaments.单克隆抗体PHF-9可识别tau蛋白磷酸化的丝氨酸404,并标记双螺旋丝。
J Neurosci Res. 1996 Oct 1;46(1):90-7. doi: 10.1002/(SICI)1097-4547(19961001)46:1<90::AID-JNR11>3.0.CO;2-G.
5
Two novel Tau antibodies targeting the 396/404 region are primarily taken up by neurons and reduce Tau protein pathology.两种新型靶向 Tau 蛋白 396/404 区域的抗体主要被神经元摄取,并减少 Tau 蛋白病理。
J Biol Chem. 2013 Nov 15;288(46):33081-95. doi: 10.1074/jbc.M113.494922. Epub 2013 Oct 2.
6
A Phosphorylation-Induced Turn Defines the Alzheimer's Disease AT8 Antibody Epitope on the Tau Protein.磷酸化诱导的构象变化决定了 Tau 蛋白上阿尔茨海默病 AT8 抗体的抗原表位。
Angew Chem Int Ed Engl. 2015 Jun 1;54(23):6819-23. doi: 10.1002/anie.201501898. Epub 2015 Apr 16.
7
Sequential phosphorylation of Tau by glycogen synthase kinase-3beta and protein kinase A at Thr212 and Ser214 generates the Alzheimer-specific epitope of antibody AT100 and requires a paired-helical-filament-like conformation.糖原合酶激酶-3β和蛋白激酶A先后在苏氨酸212和丝氨酸214位点对Tau进行磷酸化,产生抗体AT100的阿尔茨海默病特异性表位,且这需要一种双螺旋丝样构象。
Eur J Biochem. 1998 Mar 15;252(3):542-52. doi: 10.1046/j.1432-1327.1998.2520542.x.
8
Structural Basis for Recognition of a Unique Epitope by a Human Anti-tau Antibody.人类抗tau 抗体识别独特表位的结构基础。
Structure. 2018 Dec 4;26(12):1626-1634.e4. doi: 10.1016/j.str.2018.08.012. Epub 2018 Oct 11.
9
Enhancement of therapeutic potential of a naturally occurring human antibody targeting a phosphorylated Ser containing epitope on pathological tau.增强靶向病理性 tau 上含磷酸化 Ser 表位的天然人源抗体的治疗潜力。
Acta Neuropathol Commun. 2018 Jul 12;6(1):59. doi: 10.1186/s40478-018-0562-9.
10
Unique Alzheimer's disease paired helical filament specific epitopes involve double phosphorylation at specific sites.独特的阿尔茨海默病双螺旋丝特异性表位涉及特定位点的双重磷酸化。
Biochemistry. 1997 Jul 1;36(26):8114-24. doi: 10.1021/bi970380+.

引用本文的文献

1
Unveiling the structural mechanisms behind high affinity and selectivity in phosphorylated epitope-specific rabbit antibodies.揭示磷酸化表位特异性兔抗体高亲和力和选择性背后的结构机制。
J Biol Chem. 2024 Dec;300(12):107989. doi: 10.1016/j.jbc.2024.107989. Epub 2024 Nov 13.
2
Neuronal hypofunction and network dysfunction in a mouse model at an early stage of tauopathy.tau 病早期小鼠模型中的神经元功能低下和网络功能障碍。
Alzheimers Dement. 2024 Nov;20(11):7954-7970. doi: 10.1002/alz.14273. Epub 2024 Oct 5.
3
Insights into the Structural Conformations of the Tau Protein in Different Aggregation Status.揭示不同聚集状态下 tau 蛋白的结构构象。
Molecules. 2023 Jun 4;28(11):4544. doi: 10.3390/molecules28114544.
4
High-specificity antibodies and detection methods for quantifying phosphorylated tau from clinical samples.用于定量临床样本中磷酸化tau的高特异性抗体和检测方法。
Antib Ther. 2021 Feb 15;4(1):34-44. doi: 10.1093/abt/tbab004. eCollection 2021 Jan.
5
Dynamics of Internalization and Intracellular Interaction of Tau Antibodies and Human Pathological Tau Protein in a Human Neuron-Like Model.人神经元样模型中Tau抗体与人类病理性Tau蛋白的内化及细胞内相互作用动力学
Front Neurol. 2020 Nov 26;11:602292. doi: 10.3389/fneur.2020.602292. eCollection 2020.
6
Treatment of Alzheimer's Disease and Blood-Brain Barrier Drug Delivery.阿尔茨海默病的治疗与血脑屏障给药
Pharmaceuticals (Basel). 2020 Nov 16;13(11):394. doi: 10.3390/ph13110394.
7
Tau immunotherapies: Lessons learned, current status and future considerations.tau 免疫疗法:经验教训、现状和未来思考。
Neuropharmacology. 2020 Sep 15;175:108104. doi: 10.1016/j.neuropharm.2020.108104. Epub 2020 Apr 28.
8
Tau antibody chimerization alters its charge and binding, thereby reducing its cellular uptake and efficacy.Tau 抗体嵌合改变了其电荷和结合特性,从而降低了其细胞摄取和疗效。
EBioMedicine. 2019 Apr;42:157-173. doi: 10.1016/j.ebiom.2019.03.033. Epub 2019 Mar 22.

本文引用的文献

1
Tau-targeting therapies for Alzheimer disease.针对阿尔茨海默病的 Tau 靶向治疗。
Nat Rev Neurol. 2018 Jul;14(7):399-415. doi: 10.1038/s41582-018-0013-z.
2
Tau Immunotherapies for Alzheimer's Disease and Related Tauopathies: Progress and Potential Pitfalls.tau 免疫疗法治疗阿尔茨海默病和相关 tau 病:进展和潜在陷阱。
J Alzheimers Dis. 2018;64(s1):S555-S565. doi: 10.3233/JAD-179937.
3
Tau filaments in neurodegenerative diseases.神经退行性疾病中的 tau 纤维。
FEBS Lett. 2018 Jul;592(14):2383-2391. doi: 10.1002/1873-3468.13108. Epub 2018 Jul 6.
4
Tau Antibody Structure Reveals a Molecular Switch Defining a Pathological Conformation of the Tau Protein.tau 抗体结构揭示了一种分子开关,定义了 tau 蛋白的病理构象。
Sci Rep. 2018 Apr 18;8(1):6209. doi: 10.1038/s41598-018-24276-4.
5
Tau Kinetics in Neurons and the Human Central Nervous System.神经元和人中枢神经系统中的 Tau 动力学。
Neuron. 2018 Mar 21;97(6):1284-1298.e7. doi: 10.1016/j.neuron.2018.02.015.
6
Prophylactic Active Tau Immunization Leads to Sustained Reduction in Both Tau and Amyloid-β Pathologies in 3xTg Mice.预防性主动 Tau 免疫可导致 3xTg 小鼠中 Tau 和淀粉样蛋白-β 病理持续减少。
Sci Rep. 2017 Dec 6;7(1):17034. doi: 10.1038/s41598-017-17313-1.
7
Cryo-EM structures of tau filaments from Alzheimer's disease.阿尔茨海默病tau蛋白细丝的冷冻电镜结构
Nature. 2017 Jul 13;547(7662):185-190. doi: 10.1038/nature23002. Epub 2017 Jul 5.
8
Tau Antibody Targeting Pathological Species Blocks Neuronal Uptake and Interneuron Propagation of Tau in Vitro.靶向病理性tau蛋白的抗体可阻断体外培养的神经元对tau蛋白的摄取及中间神经元对tau蛋白的传播。
Am J Pathol. 2017 Jun;187(6):1399-1412. doi: 10.1016/j.ajpath.2017.01.022. Epub 2017 Apr 11.
9
Vectored Intracerebral Immunization with the Anti-Tau Monoclonal Antibody PHF1 Markedly Reduces Tau Pathology in Mutant Tau Transgenic Mice.用抗tau单克隆抗体PHF1进行载体脑内免疫显著减少突变型tau转基因小鼠的tau病理改变。
J Neurosci. 2016 Dec 7;36(49):12425-12435. doi: 10.1523/JNEUROSCI.2016-16.2016.
10
Affinity of Tau antibodies for solubilized pathological Tau species but not their immunogen or insoluble Tau aggregates predicts in vivo and ex vivo efficacy.Tau抗体对可溶性病理性Tau物种的亲和力,而非对其免疫原或不溶性Tau聚集体的亲和力,可预测体内和体外疗效。
Mol Neurodegener. 2016 Aug 30;11(1):62. doi: 10.1186/s13024-016-0126-z.